Regeneron Pharma (REGN) PT Raised to $873 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Andrew Berens raised the price target on Regeneron Pharma (NASDAQ: REGN) to $873.00 (from $710.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
